source · application/json
source_d11d1d31b46c4cc0
sha256 75c5c491cc2db369e0b646dd178bbfeabc4da98361fe1a6aacf13e2a689a334e
by researka:v2 · 2026-06-03 21:30:37.176205+04:00
{"content_hash": null, "edges": [{"from": "98a3a091-c5b2-412b-a3c6-744963f23cb2", "to": "claim_1", "type": "contains_claim"}, {"from": "98a3a091-c5b2-412b-a3c6-744963f23cb2", "to": "claim_2", "type": "contains_claim"}, {"from": "98a3a091-c5b2-412b-a3c6-744963f23cb2", "to": "claim_3", "type": "contains_claim"}], "nodes": [{"id": "98a3a091-c5b2-412b-a3c6-744963f23cb2", "title": "Bounded GLP 1 signal: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%)", "type": "publication"}, {"id": "claim_1", "text": "The cited A/B receipts support a specific working claim: Gastrointestinal adverse events were more frequent with semaglutide (82.8%) vs placebo (63.2%); Gastrointestinal events were reported in 49.1% of participants who continued subcutaneous semaglutide vs 26.1% with placebo. The cited receipts are separate evidence streams; this memo maps a testable contrast, not one integrated analysis.", "type": "claim"}, {"id": "claim_2", "text": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "type": "claim"}, {"id": "claim_3", "text": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "type": "claim"}, {"comparator": "not extracted", "directness": "primary", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_1", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity The STEP 3 Randomized Clinical Trial", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "primary", "doi": null, "effect": "not extracted", "endpoint": "not extracted", "id": "source_2", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity The STEP 4 Randomized Clinical Trial", "type": "source", "url": null, "year": 2021}, {"comparator": "not extracted", "directness": "review-level", "doi": "10.1111/obr.13792", "effect": "not extracted", "endpoint": "not extracted", "id": "source_3", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Efficacy and safety of once‐weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus—A systematic review and meta‐analysis of randomized controlled trials", "type": "source", "url": null, "year": 2024}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-022-02026-4", "effect": "not extracted", "endpoint": "not extracted", "id": "source_4", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial", "type": "source", "url": null, "year": 2022}, {"comparator": "not extracted", "directness": "primary", "doi": "10.1038/s41591-024-03015-5", "effect": "not extracted", "endpoint": "not extracted", "id": "source_5", "intervention_or_exposure": "not extracted", "population": "not extracted", "risk_of_bias": "not appraised in public sidecar", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "type": "source", "url": null, "year": 2024}], "publication_id": "98a3a091-c5b2-412b-a3c6-744963f23cb2", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 5, "included": 5, "included_or_retained": 5, "screened": 5, "wording": "5 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}
metadata
{
"researka_object_type": "publication_sidecar",
"researka_publication_id": "98a3a091-c5b2-412b-a3c6-744963f23cb2",
"researka_submission_id": "a544261c-cc24-42d3-b0b0-eb41e2d34b93",
"sidecar_name": "claim_graph.json",
"sidecar_url": "https://api.researka.org/publications/98a3a091-c5b2-412b-a3c6-744963f23cb2/sidecars/claim_graph.json"
}